Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753902 | 0.87 | MGLL (0.64) | POLBALDH1A1HSD11B1MGLLKMT2A | |
| SCHEMBL3752810 | 0.85 | MGLL (0.65) | HSD11B1MGLLKMT2A | |
| SCHEMBL3756158 | 0.81 | NPC1 (0.56) | POLBLMNAMGLLKMT2AHPGD | |
| SCHEMBL3749146 | 0.81 | FAAH (0.68) | ALDH1A1KMT2ASLC18A3 | |
| SCHEMBL3752733 | 0.80 | PKM (0.64) | ALDH1A1LMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL3759848 | 0.80 | HSD11B1 (0.61) | ALDH1A1LMNASMN1; SMN2HSD11B1MGLL | |
| SCHEMBL1720550 | 0.77 | POLB (0.89) | POLBALDH1A1LMNASMN1; SMN2HSD11B1 | |
| SCHEMBL6210853 | 0.77 | POLB (0.89) | POLBALDH1A1LMNASMN1; SMN2HSD11B1 | |
| SCHEMBL3752446 | 0.76 | MGLL (0.64) | ALDH1A1HSD11B1MGLLKMT2A | |
| SCHEMBL14338813 | 0.76 | FAAH (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| EP-2023728-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007140005-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | WO | claimed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| WO-2007140005-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, APEH | POLB 2215/4885ALDH1A1 635/4885LMNA 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.